TrialThe Lancet. Neurology2022

Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.

Alberto C S Costa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.